JPWO2020018820A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020018820A5
JPWO2020018820A5 JP2021502831A JP2021502831A JPWO2020018820A5 JP WO2020018820 A5 JPWO2020018820 A5 JP WO2020018820A5 JP 2021502831 A JP2021502831 A JP 2021502831A JP 2021502831 A JP2021502831 A JP 2021502831A JP WO2020018820 A5 JPWO2020018820 A5 JP WO2020018820A5
Authority
JP
Japan
Prior art keywords
antigen
seq
amino acid
binding domain
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021502831A
Other languages
English (en)
Japanese (ja)
Other versions
JP7319348B2 (ja
JP2021531005A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042447 external-priority patent/WO2020018820A1/en
Publication of JP2021531005A publication Critical patent/JP2021531005A/ja
Publication of JPWO2020018820A5 publication Critical patent/JPWO2020018820A5/ja
Priority to JP2023117208A priority Critical patent/JP2023134728A/ja
Application granted granted Critical
Publication of JP7319348B2 publication Critical patent/JP7319348B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021502831A 2018-07-19 2019-07-18 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 Active JP7319348B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023117208A JP2023134728A (ja) 2018-07-19 2023-07-19 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862700596P 2018-07-19 2018-07-19
US62/700,596 2018-07-19
US201862750968P 2018-10-26 2018-10-26
US62/750,968 2018-10-26
US201962793645P 2019-01-17 2019-01-17
US62/793,645 2019-01-17
PCT/US2019/042447 WO2020018820A1 (en) 2018-07-19 2019-07-18 BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023117208A Division JP2023134728A (ja) 2018-07-19 2023-07-19 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2021531005A JP2021531005A (ja) 2021-11-18
JPWO2020018820A5 true JPWO2020018820A5 (zh) 2022-07-25
JP7319348B2 JP7319348B2 (ja) 2023-08-01

Family

ID=67515169

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502831A Active JP7319348B2 (ja) 2018-07-19 2019-07-18 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用
JP2023117208A Pending JP2023134728A (ja) 2018-07-19 2023-07-19 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023117208A Pending JP2023134728A (ja) 2018-07-19 2023-07-19 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用

Country Status (16)

Country Link
US (2) US11384153B2 (zh)
EP (1) EP3823664A1 (zh)
JP (2) JP7319348B2 (zh)
KR (1) KR20210034032A (zh)
CN (1) CN112423785A (zh)
AU (1) AU2019307928A1 (zh)
BR (1) BR112021000186A2 (zh)
CA (1) CA3107126A1 (zh)
CL (1) CL2021000131A1 (zh)
CO (1) CO2021000188A2 (zh)
IL (1) IL279974A (zh)
MA (1) MA53168A (zh)
MX (1) MX2021000488A (zh)
PH (1) PH12021550031A1 (zh)
SG (1) SG11202100252SA (zh)
WO (1) WO2020018820A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110997713B (zh) 2017-06-01 2024-01-02 瑞泽恩制药公司 抗bet v 1人抗体及其使用方法
MX2022006714A (es) * 2019-12-06 2022-08-08 Regeneron Pharma Métodos de tratamiento del mieloma múltiple con anticuerpos anti-bcma x anti-cd3 bisespecíficos.
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子，其製備方法及醫藥用途
BR112022026279A2 (pt) 2020-07-01 2023-02-14 Regeneron Pharma Métodos de tratamento de alergia usando anticorpos anti-bet v 1
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
MX2023003214A (es) 2020-09-18 2023-05-24 Regeneron Pharma Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas.
CN114524878A (zh) 2020-11-23 2022-05-24 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
MX2023006604A (es) 2020-12-04 2023-06-19 Tidal Therapeutics Inc Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos.
WO2022156739A1 (zh) * 2021-01-20 2022-07-28 江苏恒瑞医药股份有限公司 特异性结合bcma和cd3的抗原结合分子及其医药用途
KR20230157315A (ko) 2021-01-28 2023-11-16 리제너론 파마슈티칼스 인코포레이티드 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
WO2023098846A1 (zh) 2021-12-03 2023-06-08 江苏先声药业有限公司 抗bcma纳米抗体及其应用
WO2023122138A1 (en) * 2021-12-22 2023-06-29 The Jackson Laboratory Humanized mouse models
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN117003871A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
US20230416396A1 (en) 2022-05-18 2023-12-28 Regeneron Pharmaceuticals, Inc. Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
US20240002331A1 (en) 2022-06-08 2024-01-04 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2024081180A1 (en) 2022-10-10 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for reducing alloantibody levels in subjects in need of solid organ transplantation
CN117186230B (zh) * 2022-12-06 2024-04-16 成都赛恩吉诺生物科技有限公司 包含亲水性氨基酸的抗人bcma纳米抗体的双特异性抗体及应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2314694A3 (en) 1999-08-17 2013-12-11 Biogen Idec MA Inc. BAFF receptor (BCMA), an immunoregulatory agent
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
DE10206325A1 (de) 2002-02-14 2003-09-04 Medinnova Ges Med Innovationen Ummantelter Mikroorganismus
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
CN102471378B (zh) 2009-06-26 2014-04-02 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
SI3095871T1 (sl) 2010-02-08 2019-06-28 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
JP2014500879A (ja) 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
RU2663123C2 (ru) 2010-11-30 2018-08-01 Чугаи Сейяку Кабусики Кайся Индуцирующий цитотоксичность терапевтический агент
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
ES2953190T3 (es) 2011-05-27 2023-11-08 Glaxo Group Ltd Proteínas de unión a BCMA (CD269/TNFRSF17)
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2914628A1 (en) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2953974B1 (en) 2013-02-05 2017-12-20 EngMab Sàrl Bispecific antibodies against cd3epsilon and bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
US20180112384A1 (en) 2013-12-30 2018-04-26 Craig Rothleitner Drainage treatment system
BR112016024546A2 (pt) 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
KR20170087486A (ko) 2014-11-20 2017-07-28 에프. 호프만-라 로슈 아게 일반 경쇄 및 이의 사용 방법
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
DK3227432T3 (en) 2014-12-05 2023-10-23 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
HUE053995T2 (hu) 2014-12-05 2021-08-30 Memorial Sloan Kettering Cancer Center B-sejt-érési antigént célzó antitestek és alkalmazási eljárások
IL290488B1 (en) 2015-04-13 2024-03-01 Pfizer Therapeutic antibodies and their uses
AU2016263198C1 (en) 2015-05-15 2023-10-05 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
HUE050556T2 (hu) 2015-08-17 2020-12-28 Janssen Pharmaceutica Nv Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai
CN108290951B (zh) 2015-09-23 2022-04-01 瑞泽恩制药公司 优化抗cd3双特异性抗体和其用途
CN108473575B (zh) 2015-11-13 2022-04-19 美国卫生和人力服务部 抗-bcma多肽和蛋白质
KR20180083936A (ko) 2015-12-01 2018-07-23 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조합 치료 및 그의 용도 및 방법
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
US10301391B2 (en) 2016-02-03 2019-05-28 Amgen Research (Munich) Gmbh BCMA and CD3 bispecific T cell engaging antibody constructs
IL260732B1 (en) 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
WO2018009904A2 (en) 2016-07-08 2018-01-11 Tumeh Paul C Compositions and treatment methods for cancer immunotherapy
DK4050034T3 (da) 2016-09-14 2024-06-03 Teneoone Inc Cd3-bindende antistoffer
IL265369B2 (en) 2016-09-23 2024-03-01 Regeneron Pharma Antibodies against (MUCIN 16) MUC16
WO2018075359A1 (en) 2016-10-18 2018-04-26 Boger Henry William Wireless power transfer for process control
CN110167964B (zh) * 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
IL300729A (en) 2016-12-21 2023-04-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
IL268206B2 (en) 2017-01-23 2024-05-01 Carsgen Therapeutics Co Ltd Antibodies directed against BCMA and their use
JP7231549B2 (ja) 2017-02-06 2023-03-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
IL268349B1 (en) 2017-02-17 2024-04-01 Hutchinson Fred Cancer Res Combination therapies for the treatment of BCMA-associated cancer and autoimmune disorders
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
MA48763A (fr) 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
IL271194B1 (en) 2017-06-20 2024-06-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
IL272304B1 (en) 2017-08-01 2024-06-01 Medimmune Llc Conjugation of antibody with monoclonal BCMA drug
CA3076972C (en) 2017-09-29 2023-09-26 Mogam Institute For Biomedical Research Anti-bcma antibody having high affinity for bcma and pharmaceutical composition for treatment of cancer, comprising same
PE20201183A1 (es) 2017-10-13 2020-11-03 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso
US11026975B2 (en) 2018-02-01 2021-06-08 Nanjing Iaso Biotherapeutics Co., Ltd. Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
SG11202011270QA (en) * 2018-05-24 2020-12-30 Janssen Biotech Inc Anti-cd3 antibodies and uses thereof
AU2020240132A1 (en) * 2019-03-21 2021-09-16 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy

Similar Documents

Publication Publication Date Title
CN107405397B (zh) 抗tim-3抗体
KR102340832B1 (ko) 항 pd-1 항체 및 그의 용도
AU2016281641B2 (en) Novel PD-1 immune modulating agents
JP6866294B2 (ja) 抗ｐｄ−ｌ１抗体
JPWO2020018820A5 (zh)
JP7474193B2 (ja) 多重特異性抗体とその作製及び使用方法
KR20180132751A (ko) Bcma 결합 분자 및 그의 사용 방법
EP3096782A2 (en) Compositions and methods for modulating and redirecting immune responses
JP7438939B2 (ja) Ｃｄ１３７を標的とする抗体とその利用方法
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
RU2019104980A (ru) Анти-icos антитела
JPWO2020132024A5 (zh)
TW202144397A (zh) 一種雙功能融合蛋白及其用途
CN114616245B (zh) 一种抗cd38的抗体及其用途
CA3147887A1 (en) Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas
RU2811477C2 (ru) Мультиспецифические антитела и способы их получения и применения
JPWO2021113701A5 (zh)
JPWO2020123664A5 (zh)
CA3232806A1 (en) B7-h4 antibody-drug conjugates for the treatment of cancer
EP4305072A1 (en) Antibodies against integrin heterodimers and uses thereof
JP2023513800A (ja) ヒト４－１ｂｂアゴニスト抗体およびその使用方法